Acute renal failure induced by renal ischemia or drugs continues to be a relevant clinical problem. Li et al. have demonstrated that proximal tubule-restricted peroxisome proliferator–activated receptor-α (PPARα) expression in transgenic mice reduced cisplatin- and ischemia/reperfusion-induced acute renal injury. Their article suggests a role for the maintenance of free fatty acid oxidation in the proximal tubule as a mechanism of nephroprotection, as well as a potential clinical utility of PPARα activators in the prevention of acute renal failure
Doxorubicin (DOX) is an anthracycline antibiotic utilized in antitumor therapy; however, its clinica...
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Per...
Peroxisome proliferator-activated receptors (PPARs) and related inflammatory and oxidative molecule ...
Our previous studies suggest that peroxisome proliferator–activated receptor-α (PPARα) plays a criti...
Our previous studies suggest that peroxisome proliferator–activated receptor-α (PPARα) plays a criti...
Acute renal failure induced by renal ischemia or drugs continues to be a relevant clinical problem. ...
Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamil...
As renal lipotoxicity can lead to chronic kidney disease (CKD), we examined the role of peroxisome p...
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Per...
Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor family of ligand-inducibl...
Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to irreversible ...
Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to irreversible ...
Alterations of PPARα and its coactivator PGC-1 in cisplatin-induced acute renal failure.BackgroundIn...
Abstract Sepsis‐associated acute kidney injury (AKI) is a significant problem in critically ill chil...
Peroxisome proliferator-activated receptor gamma (PPARγ) is a type II nuclear receptor, initially re...
Doxorubicin (DOX) is an anthracycline antibiotic utilized in antitumor therapy; however, its clinica...
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Per...
Peroxisome proliferator-activated receptors (PPARs) and related inflammatory and oxidative molecule ...
Our previous studies suggest that peroxisome proliferator–activated receptor-α (PPARα) plays a criti...
Our previous studies suggest that peroxisome proliferator–activated receptor-α (PPARα) plays a criti...
Acute renal failure induced by renal ischemia or drugs continues to be a relevant clinical problem. ...
Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamil...
As renal lipotoxicity can lead to chronic kidney disease (CKD), we examined the role of peroxisome p...
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Per...
Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor family of ligand-inducibl...
Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to irreversible ...
Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to irreversible ...
Alterations of PPARα and its coactivator PGC-1 in cisplatin-induced acute renal failure.BackgroundIn...
Abstract Sepsis‐associated acute kidney injury (AKI) is a significant problem in critically ill chil...
Peroxisome proliferator-activated receptor gamma (PPARγ) is a type II nuclear receptor, initially re...
Doxorubicin (DOX) is an anthracycline antibiotic utilized in antitumor therapy; however, its clinica...
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Per...
Peroxisome proliferator-activated receptors (PPARs) and related inflammatory and oxidative molecule ...